Time to serum creatinine recovery after percutaneous nephrostomy in advanced cervical cancer
DOI:
https://doi.org/10.48193/zvnkr885Keywords:
Percutaneous nephrostomy, Cervical Cancer, Obstructive uropathy, Serum creatinine, Renal functionAbstract
Objective: to estimate the mean time to serum creatinine normalization after percutaneous nephrostomy in patients with advanced cervical cancer and obstructive uropathy.
Methods: a retrospective observational study conducted over a two-year period at a tertiary cancer center. Women undergoing percutaneous nephrostomy between July 2023 and June 2025 were included. The primary outcome was the time to achieve serum creatinine < 1.3 mg/dL.
Results: a total of 408 nephrostomies were recorded, of which 298 (73.0%) were performed in patients with cervical cancer. After applying selection criteria, 142 patients had complete follow-up, and 103 (72.5%) achieved serum creatinine normalization. Mean time to normalization was 7.4 ± 5.8 days, with a median of 6.0 days (interquartile range 3.0–9.5). Higher baseline serum creatinine was associated with slower renal recovery. No significant differences were observed between unilateral and bilateral nephrostomies.
Limitations: the retrospective design limits control over clinical variables that may influence renal recovery.
Originality: this study provides quantitative data on renal recovery time following percutaneous nephrostomy in an oncologic population with obstructive uropathy, an aspect that remains insufficiently documented in urologic literature.
Conclusions: serum creatinine typically normalizes during the first week after percutaneous nephrostomy. Baseline renal function influences the rate of recovery and may help guide subsequent oncologic and urologic management.
References
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2024;74(3): 229–263. https://doi.org/10.3322/caac.21834.
Abu-Rustum NR, Yashar CM, Arend R, Barber E, Bradley K, Brooks R, et al. NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024. Journal of the National Comprehensive Cancer Network: JNCCN. 2023;21(12): 1224–1233. https://doi.org/10.6004/jnccn.2023.0062.
Salunkhe R, Chopra S, Kulkarni S, Shetty N, Engineer R, Mahantshetty U, et al. Outcomes of locally advanced cervical cancer presenting with obstructive uropathy: An institutional audit. Indian Journal of Cancer. 2020;57(4): 416–422. https://doi.org/10.4103/ijc.IJC_704_18.
Chalmers N, Jones K, Drinkwater K, Uberoi R, Tawn J. The UK nephrostomy audit. Can a voluntary registry produce robust performance data? Clinical Radiology. 2008;63(8): 888–894. https://doi.org/10.1016/j.crad.2007.10.021.
Lewis S, Patel U. Major complications after percutaneous nephrostomy-lessons from a department audit. Clinical Radiology. 2004;59(2): 171–179. https://doi.org/10.1016/s0009-9260(03)00336-2.
Lima DPA de, Teixeira C do NM, Abath M de B, Raposo FAN, Fontan SB. Percutaneous nephrostomy in cervical cancer patients: a retrospective analysis. Brazilian Journal of Oncology. 2023;19(continuous publication). https://doi.org/10.5935/2526-8732.20230393.
Kiende, B, Kamau, K, Cheserem, E. Impact of percutaneous nephrostomy on clinical outcomes in advanced carcinoma cervix with obstructive uropathy at Kenyatta national hospital. European Journal of Gynaecological Oncology. 2023;44(5): 21–25. https://doi.org/10.22514/ejgo.2023.075.
Mishra K, Desai A, Patel S, Mankad M, Dave K. Role of percutaneous nephrostomy in advanced cervical carcinoma with obstructive uropathy: a case series. Indian Journal of Palliative Care. 2009;15(1): 37–40. https://doi.org/10.4103/0973-1075.53510.
Muñoz Viteri MJ, Muñoz Bermeo RA, Caballero Narváez HM. Supervivencia de pacientes con cáncer de cérvix estadio clínico III y IV, sometidas a nefrostomía: Estudio descriptivo de centro único. Oncología (Guayaquil). 2022; 27–39.
Gadelkareem RA, Abdelraouf AM, Ahmed AI, El-Taher AM, Behnsawy HM. Predictors of time-to-nadir serum creatinine after drainage of bilaterally obstructed kidneys due to bladder cancer. Current Urology. 2023;17(4): 246–250. https://doi.org/10.1097/CU9.0000000000000166.
Dyer RB, Regan JD, Kavanagh PV, Khatod EG, Chen MY, Zagoria RJ. Percutaneous nephrostomy with extensions of the technique: step by step. Radiographics: A Review Publication of the Radiological Society of North America, Inc. 2002;22(3): 503–525. https://doi.org/10.1148/radiographics.22.3.g02ma19503.
Dosanjh A, Coupland B, Mytton J, King DS, Mintz H, Lock A, et al. High early mortality following percutaneous nephrostomy in metastatic cancer: a national analysis of outcomes. BMJ supportive & palliative care. 2024;14(e2): e004937, spcare-2024–004937. https://doi.org/10.1136/spcare-2024-004937.
Cordeiro MD, Coelho RF, Chade DC, Pessoa RR, Chaib MS, Colombo-Júnior JR, et al. A prognostic model for survival after palliative urinary diversion for malignant ureteric obstruction: a prospective study of 208 patients. BJU international. 2016;117(2): 266–271. https://doi.org/10.1111/bju.12963.
Ishioka J, Kageyama Y, Inoue M, Higashi Y, Kihara K. Prognostic model for predicting survival after palliative urinary diversion for ureteral obstruction: analysis of 140 cases. The Journal of Urology. 2008;180(2): 618–621; discussion 621. https://doi.org/10.1016/j.juro.2008.04.011.
Aekgawong S, Ramart P. Predicting factors for improvement of serum creatinine after percutaneous nephrostomy in adults with bilateral hydronephrosis associated with malignancy. Insight Urology. 2021;42(1): 1–6. https://doi.org/10.52786/isu.a.15.
Türk C, Petřík A, Sarica K, Seitz C, Skolarikos A, Straub M, et al. EAU Guidelines on Interventional Treatment for Urolithiasis. European Urology. 2016;69(3): 475–482. https://doi.org/10.1016/j.eururo.2015.07.041.
Ahmad MU, Siddiqui S, Ashraf FA, Iqbal R, Ehsanullah SAM, AlFayadh A, et al. Retrograde Ureteral Stents Versus Percutaneous Nephrostomy in the Management of Malignant Ureteral Obstruction: A Systematic Review and Meta-Analysis. Urology. 2024;192: 158–167. https://doi.org/10.1016/j.urology.2024.05.042.
Gauhar V, Pirola GM, Scarcella S, De Angelis MV, Giulioni C, Rubilotta E, et al. Nephrostomy tube versus double J ureteral stent in patients with malignant ureteric obstruction. A systematic review and meta-analysis of comparative studies. International Braz J Urol: Official Journal of the Brazilian Society of Urology. 2022;48(6): 903–914. https://doi.org/10.1590/S1677-5538.IBJU.2022.0225.
Zhang KP, Zhang Y, Chao M. Which is the best way for patients with ureteral obstruction? Percutaneous nephrostomy versus double J stenting. Medicine. 2022;101(45): e31194. https://doi.org/10.1097/MD.0000000000031194.
International Agency for Research on Cancer. Cervix uteri: Fact sheet. 2022.
Shah M, Blest F, Blackmur J, Laird A, Dawson S, Aning J. Malignant upper urinary tract obstruction in cancer patients: A systematic review. BJUI compass. 2024;5(5): 405–416. https://doi.org/10.1002/bco2.340.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Revista Mexicana de Urología
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
